Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1948 2
1949 3
1952 1
1953 4
1954 2
1955 2
1956 5
1957 3
1958 4
1959 3
1960 6
1961 6
1962 12
1963 27
1964 24
1965 21
1966 16
1967 16
1968 9
1969 9
1970 13
1971 15
1972 7
1973 14
1974 15
1975 22
1976 13
1977 12
1978 5
1979 20
1980 18
1981 14
1982 26
1983 30
1984 25
1985 32
1986 27
1987 33
1988 37
1989 28
1990 39
1991 40
1992 38
1993 75
1994 40
1995 63
1996 70
1997 59
1998 59
1999 68
2000 74
2001 79
2002 97
2003 76
2004 89
2005 112
2006 126
2007 115
2008 117
2009 131
2010 164
2011 200
2012 225
2013 277
2014 286
2015 305
2016 350
2017 403
2018 462
2019 484
2020 2711
2021 1680
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

8,762 results
Results by year
Filters applied: . Clear all
Page 1
Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C, Moroni G. Ponticelli C, et al. Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14. Expert Opin Drug Saf. 2017. PMID: 27927040 Review.
Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. ...
Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functi
Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.
Jorge A, Ung C, Young LH, Melles RB, Choi HK. Jorge A, et al. Nat Rev Rheumatol. 2018 Dec;14(12):693-703. doi: 10.1038/s41584-018-0111-8. Nat Rev Rheumatol. 2018. PMID: 30401979 Review.
However, the major dose-limiting toxicity of hydroxychloroquine is retinopathy that can lead to loss of vision. New highly sensitive screening methods can identify early stages of retinopathy, and studies that include these modalities have indicated a substantially higher …
However, the major dose-limiting toxicity of hydroxychloroquine is retinopathy that can lead to loss of vision. New highly sensitive …
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM; National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton-Thompson S, De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, Seethala R, Johnsky L, Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapiro N, Talmor D, O’Mara T, Kirk C, Harrison K, Kurt L, Schermerhorn M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parry B, Lavin-Parsons K, Pulido N, Lilley B, Lodenstein C, Margolin J, Brait K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, Calfee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, Rogers A, Vojnik R, Roque J, Albertson T, Chenoweth J, Adams J, Pearson S, Juarez M, Almasri E, Fayed M, Hughes A, Hillard S, Huebinger R, Wang H, Vidales E, Patel B, Ginde A, Moss M, Baduashvili A, McKeehan J, Finck L, Higgins C, Howell M, Douglas I, Haukoos J, Hiller T, Lyle C, Cupelo A, Caruso E, Camacho C, Gravitz S, Finigan J, Griesmer C, Park P, Hyzy R, Nelson K, McDonough K, Olbrich N, Williams M, Kapoor R, Nash J, Willig M, Ford H, Gardner-Gray J, Ramesh M, Moses M, Ng Gong M, Aboodi M, Asghar A, Amosu O, Torres M, Kaur S, Chen JT, Hope A, Lopez B, Rosales K, Young You J, Mosier J, Hypes C, Natt B, Borg B, Salvagio Campbell E, Hite RD, Hudock K, Cresie A, Alhasan F, Gomez-Arroyo J, Duggal A, Mehkri O, Hastings A, Sahoo D, Abi Fadel F, Gole S, Shaner V, Wimer A, Meli Y, King A, Terndrup T, Exline M, Pannu S, Robart E, Karow S, Hough C, Robinson B, Johnson N, Henning D, Campo M, Gundel S, Seghal S, Katsandres S, Dean S, Khan A, Krol O, Jouzestani M, Huynh P, Weissman A, Yealy D, Scholl D, Adams P, McVerry B, Huang D, Angus D, Schooler J, Moore S, Files C, Miller C, Gibbs K, LaRose M, Flores L, Koehler L, Morse C, Sanders J, Langford C, Nanney K, MdalaGausi M, Yeboah P, Morris P, Sturgill J, Seif S, Cassity E, Dhar S, de Wit M, Mason J, Goodwin A, Hall G, Grady A, Chamberlain A, Brown S, Bledsoe J, Leither L, Peltan I, Starr N, Fergus M, Aston V, Montgomery Q, Smith R, Merrill M, Brown K, Armbruster B, Harris E, Middleton E, Paine R, Johnson S, Barrios M, Eppensteiner J, Limkakeng A, McGowan L, Porter T, Bouffler A, Leahy JC, deBoisblanc B, Lammi M, Happel K, Lauto P, Self W, Casey J, Semler M, Collins S, Harrell F, Lindsell C, Rice T, Stubblefield W, Gray C, Johnson J, Roth M, Hays M, Torr D, Zakaria A, Schoenfeld D, Thompson T, Hayden D, Ringwood N, Oldmixon C, Ulysse C, Morse R, Muzikansky A, Fitzgerald L, Whitaker S, Lagakos A, Brower R, Reineck L, Aggarwal N, Bienstock K, Freemer M, Maclawiw M, Weinmann G, Morrison L, Gillespie M, Kryscio R, Brodie D, Zareba W, Rompalo A, Boeckh M, Parsons P, Christie J, Hall J, Horton N, Zoloth L, Dickert N, Diercks D. Self WH, et al. JAMA. 2020 Dec 1;324(21):2165-2176. doi: 10.1001/jama.2020.22240. JAMA. 2020. PMID: 33165621 Free PMC article. Clinical Trial.
IMPORTANCE: Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. OBJECTIVE: To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. ...
IMPORTANCE: Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. OBJECTIVE …
[Hydroxychloroquine for autoimmune diseases].
Danza Á, Graña D, Goñi M, Vargas A, Ruiz-Irastorza G. Danza Á, et al. Rev Med Chil. 2016 Feb;144(2):232-40. doi: 10.4067/S0034-98872016000200012. Rev Med Chil. 2016. PMID: 27092678 Free article. Review. Spanish.
Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. ...
Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. ...
Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment.
Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, Oudit GY. Yogasundaram H, et al. Can J Cardiol. 2014 Dec;30(12):1706-15. doi: 10.1016/j.cjca.2014.08.016. Epub 2014 Aug 23. Can J Cardiol. 2014. PMID: 25475472 Review.
Hydroxychloroquine interferes with malarial metabolites, confers immunomodulatory effects, and also affects lysosomal function. Clinical monitoring and early recognition of toxicity is an important management strategy in patients who undergo long-term treatment with hyd
Hydroxychloroquine interferes with malarial metabolites, confers immunomodulatory effects, and also affects lysosomal function. Clini
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, Bhattad PB, Aslam F, Ranka S, Dalia T, Chhabra L, Sanghavi D, Sonani B, Davis JM 3rd. Bansal P, et al. Ann Med. 2021 Dec;53(1):117-134. doi: 10.1080/07853890.2020.1839959. Ann Med. 2021. PMID: 33095083 Free PMC article. Review.
The purpose of this review is to elaborate on the mechanisms surrounding hydroxychloroquine. The review is an in-depth analysis of the antimalarial, immunomodulatory, and antiviral mechanisms of hydroxychloroquine, with detailed and novel pictorial explanations. ... …
The purpose of this review is to elaborate on the mechanisms surrounding hydroxychloroquine. The review is an in-depth analysis of th …
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB, Dash AP. Nina PB, et al. Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20. Indian J Public Health. 2020. PMID: 32496241 Free article. Review.
Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). ...
Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). ...
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Misra DP, Gasparyan AY, Zimba O. Misra DP, et al. Rheumatol Int. 2020 Nov;40(11):1741-1751. doi: 10.1007/s00296-020-04694-2. Epub 2020 Sep 2. Rheumatol Int. 2020. PMID: 32880032 Free PMC article. Review.
The aim of this article is to overview available evidence on the use of widely used antirheumatic drugs hydroxychloroquine, methotrexate and colchicine for additional indications. Hydroxychloroquine has endothelial stabilizing and anti-thrombotic effects. ...
The aim of this article is to overview available evidence on the use of widely used antirheumatic drugs hydroxychloroquine, methotrex …
8,762 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page